Psychedelics are revolutionizing treatment options to address a $16 trillion mental health crisis…and disrupting the $41 billion psychiatric drug market.

And with a full pipeline of compounds under development and a patent-pending process for manufacturing psilocybin, Mindset Pharma (OTC: MSSTF/CSE: MSET) is setting the table for a potentially lucrative Big Pharma takeout.

Dear Fellow Investor,

There’s no doubt that the world faces a mental health crisis.

A report by the “Lancet Commission” estimates mental health conditions like depression, anxiety, PTSD and addiction cost the global economy $16 trillion.

But here’s the thing: Big Pharma hasn’t produced a breakthrough psychiatric drug in more than a decade, and the most commonly prescribed drugs to treat mental health have a mixed track record of success.

This confluence of events has created a moment for clinical uses for psychedelic drugs like MDMA, ketamine and psilocybin (the active ingredient in “magic mushrooms”).

Research on the mental health benefits of prescribed, clinician-monitored psychedelics has created a gold rush in this sector, with Big Pharma on the lookout to snap up companies who can produce IP-protected formulations of these drugs.

It’s an environment tailor-made for Mindset Pharma (OTC: MSSTF/CSE: MSET).

Mindset has over 75 psychedelic-based drug compounds under investigation and is developing a promising new process to cost-effectively extract psilocybin from magic mushrooms.

In a red-hot M&A market for biotech companies, Mindset has the potential to deliver a big payday for early investors via an acquisition by Big Pharma.

A Revolution In Mental Health Treatment

The research clearly shows that the same magic mushrooms associated in the popular imagination with 1960s counterculture are actually a safe and effective treatment for drug-resistant depression, PTSD, anxiety and addiction.

A randomized clinical trial published by JAMA Psychiatry showed psilocybin to be an effective therapeutic option, with the study showing large, rapid and sustained antidepressant effects in patients with major depressive disorder.

Another study by the Johns Hopkins University School of Medicine produced a high success rate for participants trying to quit smoking — 80% of participants quit for six months.

Is it any wonder then that big money is starting to flow in torrents into biotech?

Save

Not A Subscriber Yet?
Get Golden Opportunities For Free

Subscribe to our Golden Opportunities e-letter to receive timely market
updates from the Gold Newsletter research team, plus video
presentations by expert speakers from the New Orleans Conference
— and the Investor’s Guide to Gold and Silver — all at no cost!

CLICK HERE to start your subscription.

Follow The Billionaires:
The Smart Money Bets Big On Biotech

Investor interest in biotech has exploded in 2021, a fact borne out by steep gains in biotech names like Prothena Corporation (up 372% in 163 days), Entera Bio (up 521% in 67 days) and Cassava Sciences (up 1,185% in 30 days).

Those kinds of returns, combined with the prospect that psychedelics in particular will disrupt the $41 billion psychiatric drug market, has some of the world’s richest investors pumping money into biotech.

Big names who are betting big on the sector include:

• Bill Gates: Invested in an Illumina start-up called GRAIL that’s developing a blood-based cancer screening test

• Jeff Bezos: Recently participated in a $76 million financing round for Nautilus Biotechnology

• Peter Thiel: The Paypal co-founder Peter Thiel recently invested in Atai Life Sciences, a $3.2 billion psychedelics biotech startup

• Warren Buffet: His company, Berkshire Hathaway, has made big investments in four biotech companies

Oh, and Shark Tank star/O’Shares ETFs Chairman Kevin O’Leary has invested in two companies specifically focused on psychedelics.

Mindset’s “Double Play” Opportunity

With heavy hitters like that providing a big capital injection into the psychedelic space, Mindset Pharma is intent on capitalizing with a “Double Play” investment opportunity.

Opportunity #1: Mindset has no less than 75 patent-pending drug compounds in its pipeline, with its most promising formulations possibly facilitating self-administered “microdosing” and clinician-monitored “macrodosing” treatments.

Better still, its MSP-1014 clinical candidate is about to enter the pre-clinical development phase — Mindset expects to submit an Investigational New Drug application to the FDA in Q2 2022.

Opportunity #2: In developing MSP-1014, Mindset has created a groundbreaking new chemical synthesis process that promises to dramatically reduce the cost of synthesizing psilocybin, the psychoactive component of magic mushrooms.

According to Joseph Araujo, Chief Scientific Officer for Mindset, the process his team has developed could reduce psilocybin production costs from between $7,000 and $10,000 per gram to cost levels measured in “hundreds, not thousands of dollars” per gram.

If this process proves effective, all by itself, it could attract the takeout interest of Big Pharma. And if MSP-1014 moves further down the drug-approval pipeline, we could see nothing short of a feeding frenzy for Mindset Pharma.

The Table’s Set For A Lucrative Exit

And this isn’t just “pie-in-the-sky” arm-waving — Big Pharma is snapping up biotech companies left in right.

Recent examples include Gilead Sciences’ all-cash, $11.9 billion acquisition of Kite Pharma, Takeda Pharmaceuticals’ $5.2 billion acquisition of Ariad Pharmaceuticals and Pfizer’s $14 billion buyout offer for Medivation.

That last deal was the culmination of a near 3,500% gain Medivation generated for early shareholders over just six years.

The key to maximizing your chances of those kinds of gains in this sector is to do your homework and place bets on companies with drug formulations and processes that can attract the attention of Big Pharma.

Based on the “double play” opportunity it offers in the high-growth, high-potential psychedelics space, Mindset Pharma belongs on your short-list of biotech names to buy.

CLICK HERE
To Learn More about Mindset Pharma